We recently compiled a list of the Trade Tensions Weigh Heavily on 10 Stocks. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other stocks.

The stock market kicked off the trading week in a bloodbath, erasing last week’s gains, with all major indices posting heavy losses following President Donald Trump’s imposition of additional 10-percent tariffs on China, and the resumption of 25-percent taxes on Mexico and Canada.

The tech-heavy Nasdaq posted the biggest losses, down 2.64 percent, followed by the S&P at 1.76 percent and the Dow Jones at 1.48 percent.

According to Trump, there was no room left for Mexico and Canada, and his 25-percent tariff for the two countries “will start.” He also signed an additional 10 percent tariff on goods from China.

The overall sentiment spilled into the performance of 10 companies, which on Monday lost as high as double digits.

To come up with Monday’s top losers, we considered only the stocks with $2 billion in market capitalization and $5 million in daily trading volume.

A pharmacist in a hospital pharmacy stands next to a row of various drug containers.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) declined by 12.25 percent on Monday to close at $6.59 each as investor sentiment was dampened by disappointing earnings results for 2024.

In a statement on Friday, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) said it nearly doubled its net loss in the last quarter of 2024 at $179 million from $93 million in the same period a year earlier, as revenues halved to $4.5 million from $10.89 million year-on-year due to the timing of projects from the company’s Roche and Genentech collaboration.

Net loss in full-year 2024 also widened by 41 percent to $463.66 million from $328.07 million despite posting a 32-percent higher revenue at $58.8 million versus $44.58 million year-on-year due to revenue recognized from its Roche and Genentech collaboration related to the completion of its first neuroscience phenomap optioned by Roche and Genentech for $30 million.

Overall RXRX ranks 7th on our list of Monday's top losers. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RXRX but trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

 

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock

 

Disclosure: None. This article is originally published at Insider Monkey.